[Rare variants of pemphigoid diseases].

Dermatologie (Heidelb)

Klinik für Dermatologie, Allergologie und Venerologie, Universität zu Lübeck, Ratzeburger Allee 160, 23562, Lübeck, Deutschland.

Published: December 2022

AI Article Synopsis

  • * There has been a notable increase in cases of these diseases, connected to an aging population and advancements in diagnostic techniques and understanding of the conditions.
  • * Key types of pemphigoid, including bullous pemphigoid and mucous membrane pemphigoid, are widely recognized, but rarer variants are emerging, highlighting the need for precise diagnosis and tailored treatment options despite the lack of clinical trial data.

Article Abstract

Pemphigoid diseases comprise a heterogeneous group of subepidermal autoimmune blistering dermatoses characterized by autoantibodies against structural proteins of the dermal-epidermal junction. Recent decades have witnessed a significant surge in the incidence of these diseases, which, in addition to general aging of the population, can be attributed to the availability of precise diagnostic methods and improved knowledge of the clinical and immunopathological spectrum. While bullous pemphigoid, mucous membrane pemphigoid, and linear IgA disease account for most pemphigoid disorders, less frequent, presumably underdiagnosed variants are increasingly becoming relevant for clinicians. These include epidermolysis bullosa acquisita, anti-p200 pemphigoid, pemphigoid gestationis, lichen planus pemphigoides, and recently defined entities such as IgM pemphigoid and Orf-induced pemphigoid. Accurate characterization and differentiation of these subtypes are not only of diagnostic relevance but may also be associated with therapeutic and prognostic implications for affected individuals. Due to the rarity of these diseases, no controlled prospective clinical trials currently exist, making their diagnosis and therapy challenging.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00105-023-05242-2DOI Listing

Publication Analysis

Top Keywords

pemphigoid
9
[rare variants
4
variants pemphigoid
4
pemphigoid diseases]
4
diseases] pemphigoid
4
pemphigoid diseases
4
diseases comprise
4
comprise a heterogeneous
4
a heterogeneous group
4
group subepidermal
4

Similar Publications

Clinical Features of Chinese Patients With Bullous Pemphigoid Induced by Immune Checkpoint Inhibitors.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao

December 2024

Department of Dermatology,State Key Laboratory of Complex Severe and Rare Diseases,PUMC Hospital,CAMS and PUMC, National Clinical Research Center for Dermatologic and Immunologic Diseases,Beijing 100730,China.

Objective To explore the clinical features and treatments of Chinese patients with bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI). Methods A retrospective analysis was conducted on 18 Chinese patients with ICI-induced BP treated in the Peking Union Medical College Hospital and 14 Chinese patients with this disease reported in the literature.Furthermore,the research data of non-Chinese patients were used for comparison to outline the clinical features and treatment responses of the Chinese patients.

View Article and Find Full Text PDF

Bullous pemphigoid and hypercoagulability: a review.

Expert Rev Clin Immunol

January 2025

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Introduction: Bullous pemphigoid (BP) is an autoimmune blistering disease characterized by autoantibodies against hemidesmosomal proteins on basal membrane zone. The presence of a high incidence of thrombotic events has led to the identification of a hypercoagulable state in BP patients.

Area Covers: This review highlights the interactions between coagulation and immune-inflammatory responses based on the current literature available, as well as individual changes of characteristic coagulation parameters in BP.

View Article and Find Full Text PDF

Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review.

Viruses

December 2024

Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131 Napoli, Italy.

The COVID-19 pandemic has encouraged the rapid development and licensing of vaccines against SARS-CoV-2. Currently, numerous vaccines are available on a global scale and are based on different mechanisms of action, including mRNA technology, viral vectors, inactive viruses, and subunit particles. Mass vaccination conducted worldwide has highlighted the potential development of side effects, including ones with skin involvement.

View Article and Find Full Text PDF

Relationship between bullous pemphigoid and metabolic syndrome and its relevant traits: a bidirectional two-sample Mendelian randomization study.

Arch Dermatol Res

January 2025

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, No.1 Shuai Fu Yuan Street, Dong Cheng District, Beijing, 100730, China.

Article Synopsis
  • Bullous pemphigoid (BP) is a chronic autoimmune blistering disease primarily affecting older adults, while metabolic syndrome (MetS) encompasses various metabolic disorders.
  • Previous observational studies have suggested a link between BP and MetS, but the results are inconsistent due to potential biases from confounding factors like corticosteroid use or age.
  • This study utilized Mendelian randomization (MR) to explore the causal relationship between BP and MetS, using genetic data, and found no significant causal association between the two or their related traits.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!